EI
VRTX icon

Elkhorn Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Elkhorn Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,614
Closed -$635K – 172
2016
Q4 		$635K Buy
+8,614
New +$701K 0.74% 93

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Elkhorn Investments's VRTX Position: Q1 2017 in Review

Elkhorn Investments sold out of Vertex Pharmaceuticals (VRTX) in Q1 2017, closing a stake of 8,614 shares — an estimated $635K sold.

Elkhorn Investments first reported a position in VRTX in Q4 2016 and held it in 1 quarter. The position peaked at $635K in Q4 2016. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

  • Elkhorn Investments reported no remaining Vertex Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Elkhorn Investments sold 8,614 Vertex Pharmaceuticals shares in Q1 2017, an estimated $635K.
  • Elkhorn Investments first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Elkhorn Investments's Vertex Pharmaceuticals position peaked at $635K in Q4 2016.
  • 522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Elkhorn Investments's 13F filing for Q1 2017, filed 2 May 2017.